1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Chul Kim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Dasatinib, Osimertinib - EGFR Gene Mutation, Nonsmall Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Chul Kim | 10 | 2016-10-01 | 2024-07-05 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
Dasatinib (1) · osimertinib (1)
United States (1)